Investigational drug · Phase 2
REGN15505
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "REGN15505"
First trial start
2026
Jul 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN15505", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
Approved drugs for the same conditions: Prostate cancer · Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN15505" as an intervention, largest first.
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07594106 · 265 participants (planned) · Start Jul 20, 2026 · Primary completion Oct 27, 2030
Drug: REGN15505; REGN15505+Cemiplimab and 1 more · For: Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC)
Sites: Goodyear, Arizona; Duarte, California; Tampa, Florida · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- PasritamigJNJ-78278343Phase 34 trials
Johnson & Johnson (Janssen) · Solid Tumor, Metastatic Castration-resistant Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ARDTPhase 32 trials
Novartis · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- FuzuloparibPhase 31 trial
Jiangsu HengRui Medicine Co., Ltd. · Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- REGN5678NezastomigPhase 23 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- GI-102Phase 22 trials
GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)
- REGN4336Phase 22 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.